How Lilly's Retatrutide Compared With Ozempic in a Head-to-Head Diabetes Trial

Eli Lilly said on Oct. 28 that its experimental drug retatrutide lowered blood sugar more and produced far greater weight loss than Ozempic at the highest approved dose in a Phase…

By Maren Holt · Senior Reporter, GLP-1

Oct 28 09:08 ETSource: Around Prague

From the source

How Lilly's Retatrutide Compared With Ozempic in a Head-to-Head Diabetes Trial
Eli Lilly said on Oct. 28 that its experimental drug retatrutide lowered blood sugar more and produced far greater weight loss than Ozempic at the highest approved dose in a Phase 3 trial of adults with type 2 diabetes. The drug is not approved anywhere, and the full data have not yet been peer-reviewed or published.

Read at aroundprague.cz

Source URL https://aroundprague.cz/en/news/us/how-lilly-s-retatrutide-compared-with-ozempic-in-a-head-to-head-diabetes-trial